| COMPANY |
Maravai LifeSciences Holdings, Inc. |
| COURT |
United States District Court for the Southern District of California |
| CASE NUMBER |
3:25-cv-00499 |
| JUDGE |
The Hon. Andrew George Schopler |
| CLASS PERIOD |
August 7, 2024, through February 24, 2025 |
| SECURITY TYPE |
Securities |
Case Background:
This is a class action lawsuit filed on behalf of those who purchased or otherwise acquired Maravai LifeSciences Holdings, Inc. (“Maravai”) (NASDAQ: MRVI) securities between August 7, 2024, and February 24, 2025, inclusive (the “Class Period”).
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Maravai lacked adequate internal controls over financial reporting related to revenue recognition; (2) as a result, Maravai inaccurately recognized revenue on certain transactions during fiscal 2024; (3) Maravai’s goodwill was overstated; and (4) that, as a result of the foregoing, Defendants’ positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Current Status of Case:
On July 29, 2025, Lead Plaintiff filed the First Amended Complaint. This action is ongoing.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.